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Abstract
Background: Integrase inhibitors are currently being incorporated into highly active antiretroviral
therapy (HAART). Due to high HIV variability, integrase inhibitor efficacy must be evaluated against
a range of integrase enzymes from different subtypes.
Methods: This study compares the enzymatic activities of HIV-1 integrase from subtypes B and C
as well as susceptibility to various integrase inhibitors in vitro. The catalytic activities of both
enzymes were analyzed in regard to each of 3' processing and strand transfer activities both in the
presence and absence of the integrase inhibitors raltegravir (RAL), elvitegravir (EVG), and MK-
2048.
Results: Our results show that integrase function is similar with enzymes of either subtype and
that the various integrase strand transfer inhibitors (INSTIs) that were employed possessed similar
inhibitory activity against both enzymes.
Conclusion: This suggests that the use of integrase inhibitors against HIV-1 subtype C will result
in comparable outcomes to those obtained against subtype B infections.
Background
Integration of viral cDNA into the host genome is one of
the definitive features of retroviral replication. Integration
is mediated by the HIV pol-encoded integrase enzyme.
Recently, integrase inhibitors have been added to the arse-
nal of antiviral drugs used in therapy. RAL (Merck) was
the first integrase inhibitor to be approved by the US Food
and Drug Administration (FDA) after clinical trials dem-
onstrated that this drug promoted a rapid and sustained
antiretroviral effect [1]. EVG (GS-9137, Gilead), another
integrase inhibitor, is currently in phase III clinical trials
[2]. Other integrase inhibitors, such as MK-2048 (Merck),
are still in pre-clinical development.
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Integrase inhibitors are active against both B- and non-B
subtypes in therapy [3,4]. Subtype C variants are respon-
sible for approximately 50% of global infections, mostly
in Sub-Saharan Africa and India [5]. It is therefore impor-
tant to determine whether the integrase enzymes of differ-
ent HIV-1 subtypes behave in a parallel manner to one
another and whether they respond similarly to the use of
integrase inhibitors of HIV-1 replication.
After viral entry and reverse transcription, reverse-tran-
scribed double-stranded blunt-ended DNA is incorpo-
rated into the host cell genome through two catalytic
activities mediated by integrase: 3' end processing and
strand transfer [6,7]. During 3' end processing, a dinucle-
otide adjacent to the conserved 3' terminal CA is excised
from the 3' end of the recently reverse transcribed HIV-1
DNA genome, generating 3' hydroxyl ends. During the
strand transfer reaction, both newly generated 3' ends are
covalently linked to target DNA in a concerted fashion via
a one-step transesterification reaction [8]. In vitro, inte-
grase can also catalyze two additional reactions: disinte-
gration and specific internal endonucleolytic cleavage
[9,10].
Variability between different HIV-1 integrases at an amino
acid level is low, ≈ 8-12%. However, sites of amino acid
differences between subtypes are often close to resistance-
related amino acids. We were therefore interested in ana-
lyzing whether such minor differences might be impor-
tant in differential acquisition of INSTI resistance
mutations in a subtype-specific manner [11]. Further-
more, natural polymorphisms in non-B integrase proteins
might alter INSTI binding or activity [12,13]. An in silico
comparison of subtype B and CRF A/G integrase predicted
that polymorphisms within subtypes might affect struc-
ture and substrate binding characteristics of IN enzymes
[13]. In this study, we compared the enzymatic activities
of subtype B and C recombinant integrases in the context
of inhibition by RAL, EVG, and the novel INSTI MK-2048.
Results
Purification of active subtype C integrase
Subtype C integrase was PCR amplified from the pINDIE-
C1 molecular clone and introduced into the expression
vector pET-15B, replacing the ORF of subtype B integrase
previously cloned by Bushman et al. [14]. To increase the
solubility of subtype C recombinant proteins, two amino
acid changes were introduced: a phenylalanine at codon
185 was changed to a histidine, and a cysteine at codon
280 was changed to a serine. These changes mimic those
previously introduced into subtype B integrase to increase
solubility and are known to not affect catalytic activity
[15,16]. Expression and purification of the subtype B and
C integrase enzymes were performed simultaneously as
previously described for subtype B integrase [15] with
minor modifications. Subtype B and C integrases were
successfully purified to > 95% homogeneity (Figure 1).
The N-terminal His tag was removed from recombinant
integrase enzymes by thrombin cleavage (Figure 1). When
the enzymatic activities of both subtype B and C purified
recombinant proteins in the presence or absence of the N-
terminal His tag were compared, no difference was
detected (data not shown). Therefore, all further experi-
ments were orchestrated using recombinant integrase that
did not undergo His tag removal.
Biochemical properties of subtype C integrase
Integrase mediates the insertion of viral cDNA into host
chromatin through two unique enzymatic activities: 3'
processing and strand transfer [6,17]. Oligonucleotides
that mimic the viral LTR ends can be utilized to analyze
these two catalytic activities in vitro. First, subtype B and C
integrases were tested for their ability to perform 3'
processing (Figure 2) and strand transfer (Figure 3). Time
course experiments show similar results for both
enzymes. Disintegration was also analyzed and subtype C
recombinant protein catalyzed this activity to a similar
extent as did subtype B recombinant protein (Figure 4).
These experiments confirm the activity of our subtype C
purified recombinant protein.
Purification of recombinant subtype B and C integrase  enzymes Figure 1
Purification of recombinant subtype B and C inte-
grase enzymes. N-terminal His tags of the enzymes were 
removed from purified subtype B and C recombinant proteins 
by thrombin cleavage. Lane 1, protein ladder (10-250 kDa) 
(New England Biolabs); INB, subtype B integrase; INC, sub-
type C integrase.Retrovirology 2009, 6:103 http://www.retrovirology.com/content/6/1/103
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Subtype B and C enzymes are inhibited to a similar extent 
by RAL, MK-2048 and EVG
RAL and EVG are INSTIs with high specific activity against
strand transfer [18,19]. MK-2048 is a prototype second-
generation INSTI with a resistance profile that is distinct
from RAL and EVG [20,21]. These three drugs have been
reported to be approximately 100-fold less specific for the
inhibition of 3' processing activity compared to strand
transfer [18,22,23].
Purified recombinant subtype B and C integrase enzymes
were incubated with increasing concentrations of inte-
grase inhibitors and corresponding templates. The results
of Table 1 and Figures 5, 6 and 7 show that 3' processing
mediated by recombinant enzymes of both subtypes was
inhibited to a similar extent (p > 0.05) by all three drugs
in the presence of MnCl2. The inhibition of 3' processing
required much higher concentrations of integrase inhibi-
tors than those needed to block strand transfer for both
subtype enzymes (Table 1), consistent with previously
reported data for subtype B integrase [18].
The strand transfer activity of subtype B and C recom-
binant proteins was inhibited by all three inhibitors. The
IC50 values of RAL for subtype B and C integrase strand
transfer were 0.37 μM and 0.15 μM, respectively, in assays
that employed Mn2+ as the cation (Figure 8, Table 1). The
IC50 values for EVG inhibition of strand transfer in Mn2+-
based assays were 0.014 μM and 0.018 μM for the subtype
B and C enzymes, respectively (Figure 9, Table 1). The IC50
values for MK-2048 against subtype B and C enzymes
were 0.075 μM and 0.08 μM, respectively (Figure 10,
Table 1).
Disintegration was inhibited by high concentrations of
MK-2048 to a comparable extent with both subtype B and
C enzymes (Figures 11, 12, 13). In contrast, neither RAL
nor EVG had much effect on this process, which is a dis-
covery that is consistent with work by others [22]. We also
evaluated strand transfer in the presence of MgCl2 rather
than MnCl2 and obtained similar IC50 values (p > 0.05)
3' Processing assay Figure 2
3' Processing assay. One representative reaction (out of 
five reactions) is illustrated. Recombinant enzyme was incu-
bated at 37°C with templates (radiolabeled double stranded 
oligonucleotide INT1/2) for the indicated times up to 120 
minutes. The 21-mer substrate and 19-mer 3' processing 
products are indicated.
Strand transfer assay Figure 3
Strand transfer assay. One representative reaction (out of 
five reactions) is depicted. Recombinant integrase enzyme 
was incubated at 37°C for 3 minutes for the initial 3' process-
ing reaction. T35/SK70, double stranded oligonucleotide sub-
strate, was added and reaction tubes were incubated at 37°C 
for the indicated times up to 120 minutes. The 21-mer sub-
strate, 19-mer 3' processing, and strand transfer products are 
indicated.Retrovirology 2009, 6:103 http://www.retrovirology.com/content/6/1/103
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for each of subtype B versus C enzymes with each of RAL,
EVG and MK-2048 in a microtiter plate system [24] (Table
2). Consistent with previous observations, IC50 values
were lower when these reactions were performed with
MgCl2 than with MnCl2 [2,24].
Inhibition of replication by integrase inhibitors was also
evaluated in cell culture based assays using cord blood
mononuclear cells (Table 3). Subtype B and C clinical iso-
lates were inhibited to a similar extent by each of RAL,
EVG and MK-2048.
Discussion
Most HIV-1 patients are infected with non-B subtypes,
most commonly subtype C [5], and subtype-specific dif-
ferences in the development of drug resistance have been
reported [25]. Therefore, it is important to understand the
activity of enzymes of different subtypes. In our study,
subtype B and C integrase enzymes were evaluated; and
the activity of integrase inhibitors against them were com-
pared, since a role for polymorphisms and structure-func-
tion differences between subtypes in drug resistance has
been demonstrated [11,12,23].
Strand transfer inhibitors have been shown as efficient
inhibitors of integration amongst a wide range of retrovi-
ruses [26]. In silico observations suggest that subtype-spe-
cific differences in regard to key amino acids in integrase,
including those close to the catalytic site, may pose an
effect on the binding of RAL [13,27,28]. Therefore, sub-
type-specific variations in DNA-binding domains could
also affect the affinity of RAL for integrase. In vitro, sub-
type B and C recombinant proteins retain similar enzy-
matic capacities in the absence of drug (Figures 2, 3, 4),
with comparable strand transfer, 3' processing and disin-
tegration activities, as measured by time course experi-
ments. We also show that RAL and EVG had similar effects
against both subtype B and C integrase enzymes, regard-
less of whether Mg2+ or Mn2+ was used as a cation (Tables
1 and 2). In addition to the foregoing, we have evaluated
the IC50 values of RAL, EVG and MK-2048 in cell-based
assays using clinical isolates of viruses of either subtype B
or subtype C origin (Table 3). No significant differences
were observed between subtypes in regard to drug suscep-
tibility. These findings are consistent with recent results
on similarities vis-à-vis biochemical activity and suscepti-
bility to antiretroviral drugs of reverse transcriptase
enzymes derived from HIV-1 subtypes B and C [29].
Conclusion
Our results provide biochemical and tissue culture evi-
dence that integrase enzymes from HIV-1 subtypes B and
C are inhibited by each of RAL, EVG and MK-2048 to a
similar extent. These findings are supportive of the use of
these inhibitors in patients infected with subtype C virus.
Disintegration assay Figure 4
Disintegration assay. One representative reaction (out of 
five reactions) is portrayed. Recombinant enzyme was incu-
bated at 37°C for the indicated times up to 120 minutes with 
disintegration template (radiolabeled oligonucleotide D). Dis-
integration template and product are indicated. (C-), Nega-
tive control lane without integrase enzyme. Top panel, 
subtype B integrase; bottom panel, subtype C integrase.
Table 1: IC50 values for RAL, EVG and MK-2048 for subtype B and subtype C integrase in Mn2+-based enzymatic assays.
3' Processing IC50
a Strand Transfer IC50
a
Subtype B Subtype C Subtype B Subtype C
RAL(μM) 1.71(0.7-4.5) 1.75(0.7-3.9) 0.37(0.2-0.8) 0.15(0.09-0.3)
MK-2048(μM) 0.58(0.28-1.20) 0.19(0.09-0.39) 0.075(0.04-0.14) 0.08(0.03-0.2)
EVG(μM) 2.66(1.44-4.91) 1.5(0.29-7.74) 0.014(0.003-0.07) 0.018(0.006-0.05)
aAll differences between subtypes were not statistically significant. 95% Confidence Intervals are indicated.Retrovirology 2009, 6:103 http://www.retrovirology.com/content/6/1/103
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Inhibition of 3' processing as a function of increasing RAL  concentration Figure 5
Inhibition of 3' processing as a function of increasing 
RAL concentration. Subtype B and C 3' processing activity 
(presented as relative percentage) in relation to increasing 
RAL concentration. This graph was prepared with GraphPad 
Prism 4.0, the combined result of quantification and analyses 
of at least 3 independent experiments.
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Inhibition of 3' processing as a function of increasing MK- 2048 concentration Figure 6
Inhibition of 3' processing as a function of increasing 
MK-2048 concentration. Subtype B and C 3' processing 
activity (presented as relative percentage) in relation to 
increasing MK-2048 concentration. This graph was prepared 
with GraphPad Prism 4.0, the combined result of quantifica-
tion and analyses of at least 3 independent experiments.
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Inhibition of 3' processing as a function of increasing EVG  concentration Figure 7
Inhibition of 3' processing as a function of increasing 
EVG concentration. Subtype B and C 3' processing activity 
(presented as relative percentage) in relation to increasing 
EVG concentration. This graph was prepared with GraphPad 
Prism 4.0, the combined result of quantification and analyses 
of at least 3 independent experiments.
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Inhibition of strand transfer as a function of increasing RAL  concentration Figure 8
Inhibition of strand transfer as a function of increas-
ing RAL concentration. Subtype B and C strand transfer 
activity (presented as relative percentage) in relation to 
increasing RAL concentration. This graph was prepared with 
GraphPad Prism 4.0, the combined result of quantification 
and analyses of at least 3 independent experiments.
0
25
50
75
100
125
Integrase subtype B
Integrase subtype C
n = 7+/- SEM
0.0001
0.001
0.01
0.1 1
10
100
1000
RAL concentration ( M)
R
e
l
a
t
i
v
e
 
S
t
r
a
n
d
 
T
r
a
n
s
f
e
r
 
A
c
t
i
v
i
t
y
 
(
%
)Retrovirology 2009, 6:103 http://www.retrovirology.com/content/6/1/103
Page 6 of 10
(page number not for citation purposes)
Inhibition of strand transfer as a function of increasing EVG  concentration Figure 9
Inhibition of strand transfer as a function of increas-
ing EVG concentration. Subtype B and C strand transfer 
activity (presented as relative percentage) in relation to 
increasing EVG concentration. This graph was prepared with 
GraphPad Prism 4.0, the combined result of quantification 
and analyses of at least 3 independent experiments.
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Inhibition of strand transfer as a function of increasing MK- 2048 concentration Figure 10
Inhibition of strand transfer as a function of increas-
ing MK-2048 concentration. Subtype B and C strand 
transfer activity (presented as relative percentage) in relation 
to increasing MK-2048 concentration. This graph was pre-
pared with GraphPad Prism 4.0, the combined result of quan-
tification and analyses of at least 3 independent experiments.
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Table 2: IC50 values for RAL, EVG and MK-2048 for subtype B 
and subtype C integrase in Mg2+-based enzymatic assays.
Strand Transfer IC50
Subtype Ba Subtype Ca
RAL (μM) 0.0047 (0.0013-0.0064) 0.0037 (0.0011-0.0086)
MK-2048 (μM) 0.0047 (0.0021-0.010) 0.0023 (0.001-0.007)
EVG (μM) 0.0017 (0.0009-0.0051) 0.0011 (0.0002-0.021)
aAll differences between subtypes were not statistically significant. 
95% Confidence Intervals are indicated.
Inhibition of disintegration as a function of increasing RAL  concentration Figure 11
Inhibition of disintegration as a function of increasing 
RAL concentration. Subtype B and C disintegration activ-
ity (presented as relative percentage) in reaction to increas-
ing RAL concentration. This graph was prepared with 
GraphPad Prism 4.0, the combined result of quantification 
and analyses of 3 independent experiments.
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Materials and methods
Oligonucleotides and reagents
Oligonucleotides were purchased from Invitrogen and
then PAGE purified. A 21-mer duplex was formed by
annealing INT1 (5'-TGTGGAAAATCTCTAGCAGT-3') and
INT2 (5'-ACTGCTAGAGATTTTCCACA-3'). The 35-mer
duplex was produced by annealing T35 (5'-ACTATACCA-
GACAATAATTGTCTGGCCTGTACCGT-3') and SK70 (5'-
ACGGTACAGGCCAGACAATTATTGTCTGGTATAGT-3').
The disintegration primer (5'-TGCTAGTTCTAGCAG-
GCCCTTGGGCCGGCGGCGCTTGCGCC-3') was heated
to 95°C and slowly cooled to achieve its secondary struc-
ture [30].
RAL and MK-2048 were obtained from Merck Pharmaceu-
ticals, Inc. EVG was obtained from Gilead Biosciences.
Cloning and Mutagenesis
Subtype C integrase was PCR amplified from the molecu-
lar clone pINDIE-C1 (accession number: AB023804) and
subcloned into the bacterial expression vector pET15B,
replacing the subtype B integrase ORF kindly obtained
from Dr. Robert Craigie, NIH.
The QuickChange II (Stratagene) site-directed mutagene-
sis kit was utilized for the introduction of the solubility
mutations F185H and C280S into subtype C integrase.
The primers utilized for this mutagenesis were INC-
FF185H (5'-GCAGTATTCATTCACAATCATAAAA-
GAAAAGGGGGG-3'), INC-RF185H (5'-CCCCCCTTT-
TCTTTTATGATTGTGAATGAATACTGC-3'), INC-FC280S
(5'-GCAGGTGCTGATTCTGTGGCAGGTAGACAG-3') and
INC-RC280S (5'-CTGTCTACCTGCCACAGAATCAGCAC-
CTGC-3').
Protein purification
Wild type and mutant His-tagged integrase proteins were
expressed in Escherichia coli BL21(DE3) and purified
under non-denaturing conditions. Bacterial cultures were
grown at 37°C. When cultures of BL21 achieved an opti-
cal density of 0.5 at 600 nm, protein expression was
induced by the addition of isopropyl-β-D-thiogalacto-
pyranoside (IPTG) to a final concentration of 1 mM. The
cultures were incubated for 3 hours at 37°C, centrifuged
(5000 rpm for 12 min), and frozen at -80°C. The pellets
were resuspended in lysis buffer (20 mM Hepes pH 7.5,
100 mM NaCl, 2 mM β-ME, protease inhibitors) and lysed
by sonication. The lysates were centrifuged (12 500 rpm
for 30 min), the supernatants discarded, and the pellets
resuspended in binding buffer (1 M NaCl, 20 mM imida-
zole, 20 mM Hepes pH 7.5, 2 mM β-ME, 100 μM ZnCl2,
protease inhibitors). Following centrifugation at 12500
rpm for 30 min, the supernatants were incubated with
nickel-nitrioltriacetic acid (Ni-NTA) agarose beads (Qia-
gen) for 1 hour at 4°C with mild agitation. Proteins were
purified utilizing propylene columns (Qiagen). His-
tagged integrase protein was then eluted, utilizing a gradi-
ent of increasing imidazole concentration (0-2 M) in elu-
tion buffer (1 M NaCl, 20 mM Hepes pH7.5, 10%
glycerol, 2 mM β-ME, 100 μM ZnCl2). The eluates were
Inhibition of disintegration as a function of increasing MK- 2048 concentration Figure 12
Inhibition of disintegration as a function of increasing 
MK-2048 concentration. Subtype B and C disintegration 
activity (presented as relative percentage) in reaction to 
increasing MK-2048 concentration. This graph was prepared 
with GraphPad Prism 4.0, the combined result of quantifica-
tion and analyses of 3 independent experiments.
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Inhibition of disintegration as a function of increasing EVG  concentration Figure 13
Inhibition of disintegration as a function of increasing 
EVG concentration. Subtype B and C disintegration activ-
ity (presented as relative percentage) in reaction to increas-
ing EVG concentration. This graph was prepared with 
GraphPad Prism 4.0, the combined result of quantification 
and analyses of 3 independent experiments.
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analyzed on 10% SDS-polyacrylamide gels with Coomas-
sie staining (Sigma-Aldrich). Proteins were dialyzed over-
night at 4°C against 1 M NaCl, 200 mM Hepes pH 7.5,
100 μM ZnCl2, 10% glycerol and 2 mM DTT in dialysis
cassettes (10,000 MWCO, ThermoScientific). The samples
were aliquoted and fast frozen at -80°C. Protein concen-
tration was measured by Bradford assay utilizing the Brad-
ford Protein Assay kit (Bio-Rad Laboratories).
Thrombin His tag exclusion
The His tags were removed from purified recombinant
subtype B and C integrases using the Thrombin Clean-
Cleave kit (Sigma) according to manufacturers' instruc-
tions. Proteins were dialyzed overnight at 4°C against 1 M
NaCl, 200 mM Hepes pH 7.5, 100 μM ZnCl2, 10% glyc-
erol and 2 mM DTT in dialysis cassettes (10,000 MWCO,
ThermoScientific).
3' processing, strand transfer and disintegration assays 
evaluated in urea gels
Oligonucleotide-based assays were performed to measure
integrase enzymatic activities. All oligonucleotide probes
were gel purified and phenol-chloroform extracted. INT1
oligonucleotide was radiolabeled using the T4 Polynucle-
otide Kinase kit (Ambion) with [γ-32P] ATP (Perkin
Elmer). Unincorporated nucleotides were discarded uti-
lizing 'NucAway columns' (Ambion). A double stranded
oligonucleotide substrate was obtained by mixing equal
concentrations of INT1 and INT2, heating to 95°C and
stepwise cooling to 37°C in 100 mM NaCl. The oligonu-
cleotides T35 and SK70 were annealed to form a second
double stranded oligonucleotide. INT1/2 mimicked the
HIV-1 U5 long terminal repeat (LTR) and acted as a sub-
strate for 3' processing. T35/SK70 acted as a site for inte-
gration of the processed INT1/2 fragment and mimicked
host DNA.
Concentrations of enzymes used in the following reac-
tions were optimized in a series of preliminary experi-
ments. Integrase reactions were performed in a buffer
containing 20 mM Hepes (pH 7.5), 30 mM NaCl, 1 mM
dithiothreitol, 125 μM ZnCl2 and 0.125 pmol dsDNA
substrate (INT1/2) in a final volume of 10 μl. Recom-
binant integrase (3.1 μM), and varying concentrations of
integrase inhibitors or water/DMSO as control, were
mixed and preincubated at 37°C for 15 min. 3' processing
reactions were initiated by addition of 7.5 mM of MnCl2
and incubated at 37°C for 3 min unless otherwise indi-
cated. For strand transfer reactions, 1.25 pmol of dsDNA
template (T35/SK70) were added and the reaction mix-
ture was further incubated at 37°C for 1 hour unless oth-
erwise indicated. Reactions were stopped by adding 5
times the volume of gel loading dye (formamide contain-
ing 1% SDS, 0.25% bromophenol blue, and 0.25% xylene
cyanol) and heating to 95°C. Reaction products were sep-
arated on 6% acrylamide, 7 M urea sequencing gels. Gels
were dried and exposed utilizing phosphorimager screens
(GE Healthcare) and scanned in a Molecular Dynamics
Typhoon Phosphorimager (GE Healthcare). Product anal-
ysis and quantification were conducted using Image-
Quant and GraphPad Prism 4.0 software. Quantification
of standard error of the mean (SEM) was performed with
GraphPad Prism 4.0 software.
The use of microtiter plates for strand transfer analysis
A microtiter plate assay was utilized to evaluate MgCl2-
mediated strand transfer as previously described [24,31].
Briefly, biotinylated oligonucleotides mimicking LTR
Table 3: EC50 values for RAL, MK-2048 and EVG for subtype B and C viruses cultured in cord blood mononuclear cells.
Subtype B EC50 Values (μM)
Viruses RAL (μM) MK-2048 (μM) EVG (μM)
5326 0.0243 ± 0.0025 0.0072 ± 0.0021 NDa
5331 0.0056 ± 0.0022 0.0010 ± 0.0002 0.0001 ± 0.00007
BK 132 0.0301 ± 0.0054 0.0148 ± 0.0032 NDa
pNL4-3 0.0082 ± 0.0013 0.0027 ± 0.0009 0.0009 ± 0.0003
IIIb 0.0012 ± 0.0005 0.0003 ± 0.0001 0.0018 ± 0.0006
Subtype C EC50 Values (μM)
Viruses RAL (μM) MK-2048 (μM) EVG (μM)
Mole 03 0.0046 ± 0.0002 0.0011 ± 0.0001 NDa
96USNG31 0.0087 ± 0.0007 0.0015 ± 0.0001 0.0008 ± 0.0006
4742 0.0206 ± 0.0090 0.0033 ± 0.0020 0.0022 ± 0.0002
BG-05 0.0067 ± 0.0009 0.0022 ± 0.0007 0.0008 ± 0.00004
HB-1 0.0015 ± 0.0004 0.0007 ± 0.0005 0.0001 ± 0.00001
aND = not doneRetrovirology 2009, 6:103 http://www.retrovirology.com/content/6/1/103
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donor DNA (5'-biotin-ACCCTTTTAGTCAGTGT-
GGAAAATCTCTAGCAGT and 5'-ACTGCTAGAGATTTTC-
CACACTGACTAAAAG) were immobilized onto black-
colour Reacti-Bind Streptavidin-coated plates (Ther-
moFisher). 313 nM recombinant enzyme was bound to
donor DNA on the plates in the presence of 25 mM MnCl2
and the plates were then washed to remove excess
unbound enzyme. 3'-FITC labelled dsDNA (5'-TGAC-
CAAGGGCTAATTCACT-FITC-3' and 3'-FITC-ACTGGTTC-
CCGATTAAGTGA-5'), used as a reaction target, was added
to the wells in 25 mM Hepes (pH 7.8), 25 mM NaCl, 2.5
mM MgCl2, and 50 μg/mL BSA [24,32] and the plate was
incubated at 37°C for 1 hour. Covalently linked target
DNA was detected through use of an anti-FITC antibody
conjugated to alkaline phosphatase (Roche) and a chemi-
luminescence substrate (CSPD Sapphire II, Applied Bio-
systems). Integrase inhibitors were added at increasing
concentrations shortly before the addition of target DNA.
Strand transfer was evaluated by chemiluminescence.
Statistical Analysis
Unpaired two-tailed t-tests were used to examine statisti-
cal significance in subtype B versus subtype C integrase
enzymatic assays using GraphPad Prism 4.0 software.
Determination of activity of integrase inhibitors in cell 
culture
Recombinant viruses (subtype B) (pNL4-3 and IIIb) and
viruses obtained from either our primary HIV infection
cohort or from long-term infected patients (subtype B and
C) were amplified as previously described [33,34]. Drug
susceptibility was measured in cell culture-based pheno-
typic assays using cord blood mononuclear cells to deter-
mine the extent of in vivo HIV replication blockage by
integrase inhibitors. 50% drug effective concentrations
(EC50s) were determined for each of RAL, EVG and MK-
2048 by monitoring the production of p24 antigen, as
previously elaborated [33].
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